HOME >> MEDICINE >> NEWS
Interferon Significantly Affects Metabolism Of Other Drugs Given To Cancer Patients, Finds University Of Pittsburgh Cancer Institute

ATLANTA, May 17 -- Cancer patients undergoing therapy with interferon alfa 2b (IFNa2b) could be overmedicated with narcotics and antidepressants commonly administered with this agent, according to a University of Pittsburgh Cancer Institute (UPCI) study showing that IFNa2b significantly depresses the activity of internal enzymes that break down these drugs. Results of the study, which have broad implications for using IFNa2b, are being presented Monday, May 17, at the annual meeting of the American Society of Clinical Oncology (ASCO) in Atlanta.

Interferons are biological response modifiers produced naturally by the body to fight infections and tumors. IFNa2b is manufactured for use in cancer treatment studies, and it can cause flu-like symptoms and depression in people receiving it.

The study focused on patients who were surgically treated for melanoma and receiving high-dose IFNa2b to prevent recurrence of the disease. Six patients got a "cocktail" of chemicals, each of which is metabolized by a different enzyme in the family of CYP450 enzymes. CYP450 enzymes operate within the liver. Results of the study showed that IFNa2b depressed the activity of two enzymes, CYP1A2 and CYP2E1, by 30 percent. These enzymes are important in metabolizing narcotics and antidepressants given to relieve side effects of IFNa2b therapy.

"What these results tell us is that we are probably intoxicating patients when we use narcotics and antidepressants together with IFNs," said John Kirkwood, M.D., professor of medicine and director of the UPCI's Melanoma Center. "The CYP enzymes in IFNa2b-treated patients simply can't metabolize these drugs effectively, so we could probably reduce the amount of these medications we're administering during the course of IFNa2b therapy."

Dr. Kirkwood and Mohammed Islam, M.D., a research associate at UPCI who is presenting this study at the ASCO meeting, are extending their studies to other CYP enzymes involved in drug metab
'"/>

Contact: Lauren Ward
wardle@msx.upmc.edu
412-624-2607
University of Pittsburgh Medical Center
17-May-1999


Page: 1 2

Related medicine news :

1. Interferons for treatment of SARS?
2. Interferon Alfa 2b extends overall survival and relapse-free survival in patients with high-risk melanoma, reports University of Pittsburgh-led U.S. I
3. University Of Pittsburgh Cancer Institute Defines First Immunologic Markers Of Interferon Effectiveness Against Melanoma
4. Significantly lower physical activity levels in obese adolescents contribute to continued obesity
5. Relaxation And Music Significantly Reduce Patients Postoperative Pain
6. Beta Blocker Significantly Improves Heart Failure Survival
7. Novel Therapy Significantly Reduces Spinal Fractures In Postmenopausal WomenWith Two Years Of Therapy
8. Study Reveals Gender Affects Lung-Cancer Development
9. HIV Patients Mental Health Affects How Seriously They Take Treatment
10. Other highlights in the March 16 JNCI
11. Other highlights in the March 2 JNCI

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/22/2019)... , ... May 22, 2019 , ... ... eClinical Solutions LLC is a finalist for the Entrepreneur Of The Year® ... prestigious business awards programs in the U.S., the program recognizes entrepreneurs and leaders ...
(Date:5/22/2019)... ST. LOUIS (PRWEB) , ... May 22, 2019 ... ... announced a new annual health observance, National Lifestyle Medicine Week, to take place ... employing each of the evidence-based therapeutic approaches of Lifestyle Medicine: a whole food, ...
(Date:5/22/2019)... ... May 22, 2019 , ... AdventHealth Ocala opened its ... Ocala the only hospital in Marion County to provide birthing services, a level-2 ... in the area. The unit will be staffed with pediatric trained nurses and ...
(Date:5/22/2019)... ... , ... NDA Partners Chairman Carl Peck, MD , announced today that ... development, has joined the firm as an Expert Consultant. Dr. Kawai has 30 years ... multiple global R&D sites in Switzerland, the US, and Japan with a focus on ...
(Date:5/21/2019)... ... May 21, 2019 , ... AltMed Florida has announced its first Orlando area ... east of Interstate 4 at exit 94) at 10 a.m. Friday, May 24, pending final ... communities of Winter Park, Apopka, Sanford and many others along the busy I-4 corridor. ...
Breaking Medicine News(10 mins):
(Date:5/22/2019)... (PRWEB) , ... May 22, 2019 , ... Adventist ... and in Hawaii, today announced it is expanding its partnership with CancerIQ ... health. The CancerIQ cancer risk assessment and management platform will be integrated into the ...
(Date:5/22/2019)... ... May 22, 2019 , ... Scientist.com, the marketplace for medical ... of Southern California (WIB-SoCal) to celebrate the 100th anniversary of the passing of ... featured in a joint social media campaign. Scientist.com will donate $1 for every ...
(Date:5/22/2019)... ... May 22, 2019 , ... The Center for Information ... its Medical Heroes Appreciation 5K Run & Walk in conjunction with the Drug Information ... Diego. The annual 5K salutes the millions of “Medical Heroes” who have given ...
Breaking Medicine Technology:
Cached News: